Newsroom

The New-York based company reports on the success at the 40th European Cystic Fibrosis Conference

SEVILLE, SPAIN (June 8, 2016) – A broad spectrum, first-in-class antimicrobial, Mul-1867, has shown tremendous potential to kill one of the most drug-resistant pathogens affecting patients with Cystic Fibrosis – multidrug-resistant S.aureus. The new data on the experimental drug was revealed today at the 40th European Cystic Fibrosis Conference by researchers from TGV-inhalonix.

June 4, 2017
NEW ORLEANS, June 4, 2017 — A next-generation antibiotic being developed by researchers at the New York-based pharmaceutical company TGV-inhalonix is significantly more effective than traditional drugs in fighting the rise in airway pathogens that cause life-threatening lung infections caused by multiresistant Aspergillus spp. from cystic fibrosis patients, according to research presented today at ASM Microbe 2017.

NEW YORK (May 9, 2017) – TGV-inhalonix, a New York drug development company behind ground-breaking Mul-1867 which gives hope to treating life-threatening, antibiotic-resistant bacterial lung infections in patients suffering from cystic fibrosis, announced that Mul-1867 has shown tremendous potential against clinical isolates of fungi from patients with cystic fibrosis and other severe lung infections.

NEW YORK (April 14, 2017) – TGV-inhalonix, a New York-based pharmaceutical company with a consistent track record in developing anti-infective agents, announced they will present data for the research study “Study Of Mul-1867 A Drug Candidate For Inhalation Therapy Of MRSA/VRSA Infections In Patients With Cystic Fibrosis In Murine Lung Infection Model” as an oral presentation at the upcoming 40th European Cystic Fibrosis Conference ( Seville, Spain, 07-10 June 2017).

NEW YORK, NY – 12/8/2016 (PRESS RELEASE JET) –TGV-inhalonix, a New York-based pharmaceutical company with a consistent track record in developing anti-infective agents, announced an upcoming new report on its most advanced novel drug candidate – MUL-1867. The new study results will be presented at The 9th Annual Biotech Showcase Conference in San Francisco, January 9-11 2017.

TGV-inhalonix, a New York-based pharmaceutical company with extensive experience developing  novel anti-infective agents, announced that it will present new findings on Mul-1867, its novel drug candidate, the first to have overcome antibiotic resistance of bacterial and fungal pathogens causing lung infections, at the world’s most significant gathering on cystic fibrosis – 30th Annual North American Cystic Fibrosis Conference (NACFC) in Orlando, October 27-29, 2016.

12